Fig. 3

Inhibition of phosphorylation of Lyn and enhancement of differentiation-inducing activity of both ATRA and VD3 by dasatinib in HL-60 cells. a After treatment with 300 nM dasatinib for 30 min, the expression levels of phosphorylation of Lyn were evaluated by flow cytometry as described in “Methods” section. b–d After treatment with 1 μM ATRA or 100 nM VD3 in the presence or absence of 300 nM dasatinib for 72 h, morphological changes and the expression profiles of CD11b and CD11c were evaluated by Wright-Giemsa staining, and flow cytometry, respectively, as described in “Methods” section. b Representative photomicrographs are shown from three independent experiments. c Flow cytometry profiles of CD11b and CD11c. d Percent of CD11b and CD11c positive cells were calculated, respectively, based on flow cytometry profiles shown in (c). Experiments were independently repeated at least three times and results are shown as mean ± SD). p-Lyn dasatinib+, the expression level of phosphorylated Lyn in the presence of dasatinib; p-Lyn dasatinib−, the expression level of phosphorylated Lyn in the presence of dasatinib. *p < 0.05 vs. control; ^# p < 0.05 vs. ATRA; ^† p < 0.05 vs. VD3